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Objective. The role of plasmacytoid dendritic
cells (PDCs) and type I interferons (IFNs) in rheuma-
toid arthritis (RA) remains a subject of controversy.
This study was undertaken to explore the contribution
of PDCs and type I IFNs to RA pathogenesis using
various animal models of PDC depletion and to moni-
tor the effect of localized PDC recruitment and activa-
tion on joint inflammation and bone damage.
Methods. Mice with K/BxN serum–induced
arthritis, collagen-induced arthritis, and human tumor
necrosis factor transgene insertion were studied. Symp-
toms were evaluated by visual scoring, quantification of
paw swelling, determination of cytokine levels by
enzyme-linked immunosorbent assay, and histologic
analysis. Imiquimod-dependent therapeutic effects were
monitored by transcriptome analysis (using quantitative
reverse transcriptase–polymerase chain reaction) and
flow cytometric analysis of the periarticular tissue.
Results. PDC-deficient mice showed exacerbation
of inflammatory and arthritis symptoms after arthrito-
genic serum transfer. In contrast, enhancing PDC
recruitment and activation to arthritic joints by topical
application of the Toll-like receptor 7 (TLR-7) agonist
imiquimod significantly ameliorated arthritis in various
mouse models. Imiquimod induced an IFN signature
and led to reduced infiltration of inflammatory cells.
Conclusion. The therapeutic effects of imiquimod
on joint inflammation and bone destruction are depen-
dent on TLR-7 sensing by PDCs and type I IFN signal-
ing. Our findings indicate that local recruitment and
activation of PDCs represents an attractive therapeutic
opportunity for RA patients.
Rheumatoid arthritis (RA) is a chronic multifac-
torial autoimmune disease (1), and secondary autoin-
flammatory mechanisms are major contributors to its
perpetuation (2). The disease etiology involves different
cell types, including innate and adaptive immune cells,
which, along with resident synovial fibroblasts, interact
to initiate and maintain an inflammatory milieu in the
affected joint (3). Our current understanding is that
interaction between the genetic background and envi-
ronmental factors triggers the disruption of tolerance
to self antigens, which leads to activation of both B
and T cells. This B and T cell activation in turn leads to
a proinflammatory loop including cytokine production,
aberrant adaptive response, neovascularization, and
synoviocyte activation. To control or avoid this patho-
genic interplay of cells in the synovium of RA patients,
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drugs that affect different cellular and/or molecular
actors have been developed (4), and major successes
have been obtained in the past 15 years (5,6), especially
with biologic agents that target various cytokines (7).
These treatments, however, have serious side effects in
some cases (4).
While currently available therapies aim to con-
trol the various actors in RA pathogenesis, dendritic
cells (DCs), which are at the crossroads between innate
and adaptive immune cells, have not received due
attention as potential therapeutic targets. Of interest is
a subpopulation of DCs, the plasmacytoid DCs (PDCs),
which are defined by their capacity to secrete large
amounts of type I interferons (IFNs). IFNs are inflam-
matory cytokines of paramount importance in the
pathophysiology of many autoimmune or autoinflam-
matory diseases (8). However, while the involvement of
type I IFNs in RA pathogenesis is substantiated by sev-
eral observations, such as an association with single-
nucleotide polymorphisms in genes like IFN regulatory
factor 5 (IRF-5) or IRF-8 (9) or the presence of the
so-called “IFN signature” in the peripheral blood cells
of RA patients (10,11), the precise effect of these
cytokines remains a subject of controversy. This is par-
ticularly well evidenced by the dichotomy between the
positive and promising action of type I IFNs adminis-
tered intraarticularly in animal models (12) and the
subsequent absence of biologic effects when these
molecules were delivered in the context of unsuccessful
clinical trials (13). Hence, the precise role of type I
IFNs, either beneficial or detrimental in RA pathogen-
esis, remains a subject of debate. Therefore, the poten-
tial to target these cytokines or the cells that produce
them (PDCs) in order to expand the spectrum of mole-
cules that may be prescribed to RA patients is still large-
ly unexplored, despite obvious medical needs (among
RA patients, 30–40% do not respond to biologic agents
and complete remission is achieved in only 25–30%
[4]) and clear evidence demonstrating the presence of
PDCs in the synovium of RA patients (14).
The present study aimed to clarify this issue. In
various mouse models of PDC depletion in which joint
inflammation was triggered by arthritogenic K/BxN
serum transfer, we observed worsened symptoms, sug-
gesting that PDCs exert protective functions in RA. We
next showed that mobilization and activation of PDCs
upon topical application of the Toll-like receptor 7
(TLR-7) ligand imiquimod induces a notable reduction
in the inflammation and bone erosion seen in 3 differ-
ent mouse models of RA. This effect is accompanied
by local recruitment of PDCs and reduced neutrophil
infiltrates in the joint, as revealed by flow cytometry
and transcriptome analysis. Importantly, the beneficial
effects of imiquimod require type I IFN signaling.
These observations highlight the potential efficacy of
imiquimod, a molecule approved by the Food and Drug
Administration, and its possible future use as the first
topical treatment for RA.
MATERIALS AND METHODS
Mice. Ikaros-deficient mice (IkL/L mice) have been
described previously (15). TLR-7/ mice were provided
by Lena Alexopoulou, PhD (Centre d’Immunologie de
Marseille-Luminy, Marseille, France), BDCA2-DTR mice
were obtained from Maria Sibilia, MD (Medical University of
Vienna) with the agreement of Marco Colonna, MD (Wash-
ington University, St. Louis, MO), and IFNAR-1/ mice
were obtained from Rolf Zinkernagel, MD (University Hospi-
tal Zurich, Zurich, Switzerland). Mice used in all experiments
were age and sex matched. Animals were maintained under
pathogen-free conditions in the animal care facility of our lab-
oratory (Institut d’Immunologie et d’Hematologie, Strasbourg,
France). Human tumor necrosis factor (TNF)–transgenic mice
were provided by George Kollias, MD (Biomedical Sciences
Research Center Alexander Fleming, Vari, Greece) and main-
tained in the animal facility of the Medical University of
Vienna.
Study approval. Handling of mice and experimental
procedures were conducted in accordance with French law
for the protection of laboratory animals. The procedures were
approved by the Service Veterinaire de la Prefecture du Bas-
Rhin (Strasbourg, France) and by the Regional Ethics Com-
mittee for Animal Experimentation of Strasbourg University,
under authorization number 01608.01. Experiments per-
formed in Vienna were approved by the animal ethics com-
mittee of the Medical University of Vienna and comply with
institutional guidelines (BMWF-66.009/0103-C/GT/2007 and
BMWF-66.009/0241-II/3b/2011). For additional information
on study methods, see Supplementary Methods, available on
the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40225/abstract.
Statistical analysis. To analyze the time-dependent evo-
lution of several parameters (paw thickness, joint arthritis
score, and weight), we calculated the area under the curve and
used the Mann-Whitney nonparametric unpaired 2-tailed test
to compare 2 independent groups using GraphPad 5.04 soft-
ware. Similarly, interleukin-6 (IL-6) expression, quantitative
reverse transcriptase–polymerase chain reaction (qRT-PCR)
results, quantification of cell population, and OsteoMeasure
data were analyzed by Mann-Whitney 2-tailed unpaired test.
P values less than 0.05 were considered significant.
RESULTS
PDC deficiency exacerbates joint inflammation
in a serum-transfer model of arthritis. To evaluate the
contribution of PDCs to RA pathogenesis, we first used
a serum-transfer model of arthritis (in which B and T
cells are dispensable) (16). In this model, arthritogenic
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K/BxN serum was injected into control mice and IkL/L
mice, which have a hypomorphic mutation that causes
a deletion of peripheral PDCs, while myeloid cells (like
neutrophils) and lymphoid cells (B, T, and natural killer
cells) remain unaffected (15,17). (See Supplementary
Figures 1A–C, available on the Arthritis & Rheumatol-
ogy web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.40225/abstract.)
The severity of joint inflammation was evaluated
by measurement of paw thickness. IkL/L mice exhibited
a significant increase in joint swelling compared to con-
trols from days 6 to 15 (Figure 1A). Visual scoring of
the joints (considering redness and swelling) yielded
similar results (Supplementary Figure 1D). Increased
weight loss in IkL/L mice compared to controls (Fig-
ure 1B) additionally indicated that PDC depletion pro-
moted more severe systemic effects in IkL/L mice upon
serum transfer. These observations were confirmed by
cytokine quantification showing increased IL-6 and IL-
1b gene expression in the paws of IkL/L mice at the
peak of the response (on day 9) (Figures 1C and D)
and augmented secreted IL-6 in the blood of mutant
animals on days 5 and 9 (Figures 1E and F). Histologic
examination was performed on day 9. (Representative
tartrate-resistant acid phosphatase staining is shown
in Figures 1K and L.) Histologic analysis indicated
increased inflammatory infiltrates, osteoclast numbers,
and importantly, bone erosion in the paws of IkL/L mice
(Figures 1G–I).
While the serum-transfer model of arthritis is a
model of acute disease characterized by quick recovery,
we observed lasting bone erosion in IkL/L mice 22 days
after the induction of arthritis (Figure 1J). Of note,
IkL/L mice did not spontaneously develop any obvious
bone defects, as evidenced by an exhaustive bone mor-
phometric analysis (Supplementary Table 1, available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40225/abstract).
Furthermore, similar numbers of osteoclasts were
obtained upon RANKL stimulation of bone marrow
cells from wild-type and IkL/L mice (Supplementary
Figure 1E), indicating that osteoclastogenesis is not
affected by the Ikaros mutation. Finally, we also
detected a population of infiltrating PDCs in the
periarticular tissue of control mice, but not IkL/L mice,
with serum-transfer arthritis on day 10 (Supplementary
Figures 1F–I). (These were CD45+B220lowPDCA1+
cells, which also stain with anti-CCR9 antibody, but not
anti–Siglec H antibody [results not shown].) Of note,
increased immune cell (CD45+) infiltrate, of which
neutrophils are likely the majority (18), was
observed in IkL/L mice compared to wild-type mice
(Supplementary Figure 1H). Taken together, these data
indicate that the presence of PDCs is important to
limit or resorb the joint inflammation triggered by
serum transfer.
To further analyze the role of PDCs, we used 2
different ablation methods. First, mice were injected
with 120G8 monoclonal antibody (mAb) (19), which is
specific for bone marrow stromal antigen 2 (tetherin/
CD317), predominantly expressed by mouse PDCs (20),
and then inflammatory arthritis was examined following
K/BxN serum transfer. Paw swelling was significantly
increased in mice receiving 4 injections of 120G8 mAb
compared to those in which a control isotype antibody
was injected (Supplementary Figure 2A, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40225/abstract). Serum IL-6
levels quantified 5 days after arthritis induction were
increased in 120G8-treated mice compared to controls
(Supplementary Figure 2B). However, histologic analysis
did not reveal marked differences between PDC-
depleted and control animals (Supplementary Figures
2C–G), which might be related to the resistant popula-
tion of PDCs (B220+PDCA1+CD11c+) remaining after
injections of 120G8 mAb (Supplementary Figures 2H
and I) or, alternatively, to the consumption of comple-
ment caused by the iterative mAb injections.
Indeed, inflammation in the serum-transfer mod-
els of arthritis is particularly complement dependent
(21). To circumvent this, we induced PDC ablation
in BDCA2-DTR–transgenic mice (22). Using this
approach, we first noticed that 5 successive injections of
diphtheria toxin (on days 0, 2, 4, 6, and 8) partially
phenocopied the IkL/L mutation. Indeed, a significant
increase in paw swelling (Supplementary Figure 3A) and
systemic IL-6 secretion on day 5 (Supplementary Fig-
ure 3B) was observed in DTR-transgenic mice upon
diphtheria toxin injection. However, qRT-PCR quantifi-
cation of IL-6 and IL-1b transcripts on day 9 did not
show any difference between control and BDCA2-DTR
mice (Supplementary Figure 3C). Accordingly, this pro-
tocol, although efficient, did not enable PDC depletion
as extensive as that seen in in IkL/L mice (Supplementary
Figures 3D and E). Therefore, consistent with our previ-
ous analysis of 120G8-depleted mice, BDCA2-DTR–
transgenic animals did not exhibit enhanced arthritis
characteristics upon histologic analysis (Supplementary
Figures 3F–H). Taken together, these data suggest a pro-
tective role of PDCs in inflammatory arthritis.
Dampened inflammation and reduced bone
destruction upon PDC recruitment and activation in
mouse models of RA. We next sought to recruit and
activate PDCs with the aim of controlling experimental
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inflammatory arthritis. Imiquimod, a TLR-7 agonist,
has been shown to induce psoriasis-like lesions upon
topical application via the recruitment and activation
of PDCs (23,24). We first tested the effect of a cream
containing 5% imiquimod in the serum-transfer arthritis
model (see Supplementary Video, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40225/abstract). We observed
that 2 topical applications of 0.75 lg of imiquimod on the
inflamed joints on days 4 and 9 significantly reduced
swelling (Figures 2A and B). This was accompanied by a
decrease in local IL-6 and IL-1b gene expression
(Figures 2C and D) and systemic IL-6 secretion (Fig-
ure 2E). Of note, increased IFNb secretion was also
observed after application of imiquimod on day 5 (Fig-
ure 2F). This reduced inflammation enhanced bone qual-
ity, as seen by decreased erosion in the imiquimod-treated
group compared to the vehicle-treated group (Figures 2G
and H).
Importantly, imiquimod application increased
the population of periarticular PDCs in wild-type ani-
mals (compared to vehicle-treated mice, see Supple-
mentary Figure 1F), but not in IkL/L mutant mice
(Figures 2I–K), in which the treatment did not appear
Figure 1. Enhanced arthritis symptoms in Ikaros mutant (IkL/L) mice upon K/BxN serum transfer. A, Clinical quantification of paw swelling in
wild-type and IkL/L mice with serum-transfer arthritis. B, Effect of serum-transfer arthritis on the weight of wild-type and IkL/L mice. In A and B, val-
ues are the mean  SEM. D0 = day 0. C and D, Relative quantification (RQ) of interleukin-6 (IL-6) (C) and IL-1b (D) expression in the paws of
wild-type mice (n = 4) and IkL/L mice (n = 4) by quantitative reverse transcriptase–polymerase chain reaction 9 days after serum-transfer arthritis
induction. E and F, Quantification of serum IL-6 in wild-type mice (n = 6) and IkL/L mice (n = 6) by enzyme-linked immunosorbent assay 5 days (E)
and 9 days (F) after serum-transfer arthritis induction. G–I, Histomorphometric quantification of the area of inflammation (G), number of osteo-
clasts (H), and bone erosion area (I) in the hind paws of wild-type mice (n = 8) and IkL/L mice (n = 6) 9 days after serum-transfer arthritis induction.
J, Histomorphometric quantification of bone erosion in the hind paws of wild-type mice (n = 8) and IkL/L mice (n = 6) 22 days after serum-transfer
arthritis induction. In C–J, symbols represent individual mice; horizontal lines and error bars show the mean  SEM. K and L, Representative
images of tartrate-resistant acid phosphatase staining of the hind paws of wild-type mice (K) and IkL/L mice (L) 9 days after serum-transfer arthritis
induction. Original magnification 9 5. * = P < 0.05; ** = P < 0.01; *** = P < 0.001. Results are representative of at least 2 experiments.
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to be effective either locally (as measured by paw
swelling and visual score) or systemically (as measured by
weight) (Figures 2L–N). Furthermore, IkL/L mice trea-
ted with vehicle and those treated with imiquimod
exhibited similar joint inflammation (Supplementary
Figures 4A–E, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
40225/abstract), although a weak and transient IFN
response was noticed in IkL/L mice following imiquimod
application (Supplementary Figure 4F), which can
Figure 2. Reduction in joint inflammation and bone damage in serum-transfer arthritis upon topical application of imiquimod (IMQ). A–H show
results for C57BL/6 wild-type mice (n = 6 per group in C and D; n = 10 vehicle-treated mice and 8 imiquimod-treated mice in E; n = 6 vehicle-
treated mice and 4 imiquimod-treated mice n F; n = 6 vehicle-treated mice and 8 imiquimod-treated mice in H). Animals were treated with topical
application of 5% imiquimod or a vehicle cream on the ankle joints of the front and hind paws on days 4 and 9. A and B, Paw swelling (A) and
clinical score (B) in mice with serum-transfer arthritis. C and D, Relative quantification (RQ) of interleukin-6 (IL-6) (C) and IL-1b (D) expression
in mouse paws by quantitative reverse transcriptase–polymerase chain reaction 9 days after serum-transfer arthritis induction. E, Quantification of
serum IL-6 by enzyme-linked immunosorbent assay (ELISA) 9 days after serum-transfer arthritis induction. F, Quantification of serum interferon-
b (IFNb) by ELISA 5 days after serum-transfer arthritis induction. G, Representative images showing tartrate-resistant acid phosphatase staining
of mouse hind paws 9 days after serum-transfer arthritis induction. Bars = 500l. H, Histomorphometric quantification of bone erosion in mouse
hind paws 9 days after serum-transfer arthritis induction. I and J, Representative flow cytometric analysis of joint-infiltrating plasmacytoid den-
dritic cells (PDCs; CD45+PDCA1+B220+) in wild-type (Ik+/+) mice (I) and IkarosL/L (IkL/L) mice (J) treated with topical application of imiqui-
mod 5%. K, Quantification of joint-infiltrating PDCs in wild-type mice (n = 3) and IkL/L mice (n = 3) treated with topical application of
imiquimod 5%. L–N, Paw thickness (L), visual score (M), and weight (N) in wild-type mice and IkL/L mice treated with topical application of imi-
quimod 5%. In A, B, and L–N, values are the mean  SEM. In C–F, H, and K, symbols represent individual mice; horizontal lines and error bars
show the mean  SEM. * = P < 0.05; ** = P < 0.01. Results are representative of at least 2 experiments. D0 = day 0.
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reflect the presence of a small proportion of PDCs, or
alternatively, the response of imiquimod-responding
cells, such as conventional DCs, expressing low levels of
TLR-7.
Next, we induced joint inflammation using serum
transfer and treated mice (on days 4 and 9) in the right
hind paw only. Paw thickness and visual score did not
differ significantly between the contralateral (untreated)
Figure 3. Reduction in joint inflammation and bone damage in DBA/1 mice with collagen-induced arthritis (CIA) by topical application of
imiquimod (IMQ). A, Paw swelling in mice with CIA. Animals were treated with topical application of 5% imiquimod or a vehicle cream on the
ankle joints of the front and hind paws on days 28, 31, 36, 41, and 46. Values are the mean  SEM. D0 = day 0. B and C, Quantification of serum
interleukin-6 (IL-6) by enzyme-linked immunosorbent assay in vehicle-treated mice (n = 7) and imiquimod-treated mice (n = 6) 32 days (B) and 50
days (C) after induction of CIA. Symbols represent individual mice; horizontal lines and error bars show the mean  SEM. D, Representative images
of tartrate-resistant acid phosphatase staining of the hind paws of vehicle-treated mice (left) and imiquimod-treated mice (right) 50 days after CIA
induction. Bars = 500l. E–G, Histomorphometric quantification of the area of inflammation (E), number of osteoclasts (F), and bone erosion area
(G) in the hind paws of vehicle-treated mice and imiquimod-treated mice 50 days after CIA induction. Symbols represent individual mice; horizontal
lines and error bars show the mean  SEM. * = P < 0.05; ** = P < 0.01; *** = P < 0.001. Results are representative of at least 2 experiments.
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paws of treated mice and the paws of mice that received
no imiquimod, thereby indicating that imiquimod exerts
its maximal effects at the site of application (Supplemen-
tary Figures 5A–C, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.40225/abstract).
To expand these observations to alternative mod-
els of RA (18), we also tested the effect of iterative
imiquimod applications in DBA/1 mice with collagen-
induced arthritis (CIA). We initiated imiquimod appli-
cations on day 28, when the first signs of inflammation
appeared, and then repeated the treatment 4 times (on
days 31, 36, 41, and 46). This led to a significant reduc-
tion in paw swelling compared to that in animals given
the vehicle cream (Figure 3A and Supplementary Fig-
ure 6, available on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.40225/
abstract). This observation was corroborated by
decreased IL-6 secretion in the imiquimod-treated
group at the peak of symptoms (on day 50) (Figure 3B).
Histologic analysis of the paws revealed a marked
reduction in the area of inflammation, the numbers of
osteoclasts per hind paw, and, importantly, the bone ero-
sion area (Figures 3E–G). In addition, imiquimod appli-
cation induced a significant decrease in the production
of anti–type II collagen antibodies on day 50 (Supple-
mentary Figure 7, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.40225/abstract).
Finally, we administered serial imiquimod (or
vehicle) applications to human TNF–transgenic mice,
which are considered to be a relevant model of erosive
arthritis (25). Each mouse received treatments on 1 hind
paw. As seen in Figure 4, mice receiving imiquimod
exhibited reduced arthritis symptoms, as monitored by
histologic parameters.
Imiquimod-mediated therapeutic effects require
type I IFN signaling. Having established the beneficial
effect of topical imiquimod on joint inflammation, we
aimed to describe its mechanism of action. First, we
confirmed that topical application of imiquimod
requires signaling through TLR-7 to induce its protec-
tive effects on joint inflammation. As shown in
Supplementary Figure 8 (available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40225/abstract), application of imi-
quimod on days 4 and 9 had no beneficial effects on
local arthritis symptoms (increased joint swelling and
score) (Supplementary Figures 8A and B) or systemic
arthritis symptoms (weight loss) (Supplementary
Figure 8C) caused by K/BxN serum transfer in TLR-7/
animals. These observations correlate with the
steady-state levels of circulating IL-6 seen on day 5
(Supplementary Figure 8D) and lack of PDC mobiliza-
tion in the joints (Supplementary Figures 8E and F).
We gathered additional details by first using flow
cytometry to analyze the effects of imiquimod applica-
tion on the innate immune cell populations present in
the periarticular tissue (gating strategy is shown in Sup-
plementary Figure 9, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40225/abstract). In addition, we per-
formed a transcriptome analysis of this microenviron-
ment. We noticed that application of imiquimod (but
not the vehicle cream) to the joints of wild-type mice
on days 4 and 9 following K/BxN serum transfer drasti-
cally reduced the CD45+ immune cell infiltrate (Fig-
ure 5A). (See also Supplementary Figure 10, available
on the Arthritis & Rheumatology web site at http://on
linelibrary.wiley.com/doi/10.1002/art.40225/abstract, for
absolute numbers of cells present in the joint.) This is
consistent with reduced swelling and a decrease in the
Figure 4. Reduced severity of arthritis symptoms in human tumor necrosis factor–transgenic mice treated with topical application of imiquimod
(IMQ). Animals were treated with vehicle (n = 6) or imiquimod 5% (n = 6). A, Histomorphometric quantification of the area of inflammation in
vehicle-treated and imiquimod-treated mice. B, Number of osteoclasts per hind paw in vehicle-treated and imiquimod-treated mice. C, Bone ero-
sion area in the hind paws of vehicle-treated and imiquimod-treated mice. Symbols represent individual mice; horizontal lines and error bars show
the mean  SEM. * = P < 0.05. Results are representative of at least 2 experiments.
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expression of markers of inflammation (IL-6 and IL-1)
(Figures 2C–E).
Furthermore, imiquimod induced the recruit-
ment or the activation of PDCs, the proportion of
which increased in the periarticular tissue of treated
animals (Figures 5B and F), while absolute numbers
remained steady (Supplementary Figure 10B). These
changes were accompanied by reduced numbers of neu-
trophils (Figure 5D) and conventional DCs (Fig-
ure 5E). Consistent with these observations, we found
that imiquimod induced changes in transcriptome
profiling, such as decreased expression of the genes
encoding the neutrophil chemoattractants CXCL1 and
CXCL2 (26), and increased expression of CCL2 and
Figure 5. Induction of major cellular and transcriptional changes in the inflamed joints of mice with serum-transfer arthritis treated with
imiquimod (IMQ). A, Quantification of immune (CD45+) cells by flow cytometry. B–E, Proportion of plasmacytoid dendritic cells (PDCs) (B),
macrophages (Mac) (C), neutrophils (Neutro) (D), and conventional DCs (CDCs) (E) in the periarticular tissue of vehicle-treated C57BL/6 mice
(n = 4) or imiquimod-treated C57BL/6 mice (n = 6) 9 days after serum-transfer arthritis induction. In A–E, symbols represent individual mice;
horizontal lines and error bars show the mean  SEM. F, Proportions of conventional DCs, neutrophils, macrophages, and PDCs in CD45+ cells
in the periarticular tissue of vehicle-treated C57BL/6 mice (n = 4) and imiquimod-treated C57BL/6 mice (n = 6) 9 days after serum-transfer
arthritis induction. Bars show the mean  SEM. G, Heatmap depicting transcriptional profiling in the paws of vehicle-treated C57BL/6 mice
(n = 10) and imiquimod-treated C57BL/6 mice (n = 12) 9 days after serum-transfer arthritis induction. * = P < 0.05; ** = P < 0.01.
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CCL5, the products of which attract monocytes (27)
and PDCs (28) (Figure 5G and Supplementary Fig-
ure 11, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40225/abstract).
Importantly, the ratio of arginase 1 to inducible
nitric oxide synthase indicated that infiltrating macro-
phages of imiquimod-treated mice are likely polarized
toward alternative activation (M2) (29), which is consis-
tent with reduced IL-6, IL-1, and CD14 expression
and reduced major histocompatibility complex class II
staining in macrophages (Supplementary Figure 9D).
Of note, a clear IFN signature was evidenced by
increased levels of IRF-7 and several IFN-stimulated
genes (ISGs), such as Mx-1, IFN-induced protein with
tetratricopeptide repeats 1, and CXCL10 transcription.
The lack of changes in the expression of IFNb, IFNa4,
and IFNa2 might reflect the fact that these genes are
fast, non-lasting responders. Finally, the quantification
of transcripts encoding matrix metalloproteinases
(MMPs), which are important effectors participating in
the bone damage following serum-transfer arthritis,
confirms the protective effect of imiquimod. Indeed,
expression of MMP-8 (whose knockout increases bone
erosion, thereby classifying this MMP as “protective”
[30]) was augmented by imiquimod application, while
Figure 6. Type I interferon signaling is necessary for imiquimod (IMQ)–mediated antiinflammatory and bone-protective effects. A–C, Paw thickness
(A), visual score (B), and weight (C) in IFNAR1/ mice with serum-transfer arthritis treated with vehicle or imiquimod on days 4 and 9 after arthri-
tis induction. D0 = day 0. D, Quantification of serum interleukin-6 (IL-6) by enzyme-linked immunosorbent assay in vehicle-treated IFNAR1/
mice (n = 5) and imiquimod-treated IFNAR1/ mice (n = 6) 5 days after serum-transfer arthritis induction. E, Relative quantification (RQ) of IL-
1b transcripts in the paws of vehicle-treated IFNAR1/ mice (n = 10) and imiquimod-treated IFNAR1/ mice (n = 12) by quantitative reverse
transcriptase–polymerase chain reaction 9 days after serum-transfer arthritis induction. F–H, Histomorphometric quantification of the area of inflam-
mation (F), number of osteoclasts (G), and bone erosion area (H) in the hind paws of vehicle-treated IFNAR1/ mice (n = 10) and imiquimod-treat-
ed IFNAR1/ mice (n = 12) 9 days after serum-transfer arthritis induction. In A–C, values are the mean  SEM. In D–H, symbols represent
individual mice; horizontal lines and error bars show the mean  SEM. Results are representative of at least 2 experiments. NS = not significant.
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transcripts encoding the “pathogenic” MMP-9 (31) and
MMP-13 (32) were slightly reduced.
Quantitative RT-PCR of a set of osteoclast-
related genes additionally showed reduced expression
of the calcitonin receptor gene in the imiquimod-
treated samples, consistent with the effects of the
treatment on bone erosion, as seen on histologic exami-
nation. Transcripts encoding IL-10 remained below
detection levels in this assay (results not shown). This
analysis showed that topical application of imiquimod
induced profound changes in the cellular cocktail that
infiltrates the joint after serum-transfer arthritis induc-
tion. Most of these changes (such as M2 polarization
of macrophages and the reduced proportion of neu-
trophils) likely account for the beneficial effects of
imiquimod on joint inflammation and subsequent bone
damage induced in mice with serum-transfer arthritis.
Finally, the transcriptomic “IFN signature”
prompted us to evaluate the importance of type I IFN
signaling in the antiinflammatory effects mediated by
application of imiquimod. We examined the impact of
imiquimod application in IFNAR/ mice upon K/BxN
serum transfer. The data demonstrated that absence
of type I IFN signaling impairs imiquimod-dependent
antiinflammatory effects, as determined by paw swell-
ing, weight, IL-6 expression, and histologic features of
the arthritic joints (Figure 6). Taken together, our find-
ings indicate a stepwise scenario whereby the sequence
imiquimod/TLR-7/PDCs/type I IFN creates an appro-
priate environment for dampening joint inflammation
and reducing subsequent bone damage.
DISCUSSION
The role of type I IFNs in the pathogenesis of RA
remains a matter of controversy (10). Several previous
studies pointed to an association between increased
type I IFN secretion and subsequent transcription of
ISGs (the so-called “IFN signature” [33]) in some RA
patients (34). This suggests that this cytokine family
exerts proarthritogenic effects, which correlate with
cases of disease induction in patients with hepatitis C
virus treated with PEGylated IFN (35). However, several
mouse studies have challenged this concept. For
instance, IRF-7–deficient mice are resistant to serum-
transfer arthritis (36), and several authors have reported
beneficial effects of IFNb injections in mice (12) or rhe-
sus monkeys (37) after arthritis induction. This led to a
first clinical trial involving a small number of patients (n
= 11) (38) whose promising results could not be repro-
duced when the number of subjects was scaled up (n =
209) (13). Furthermore, a pathogenic role of type I IFNs
is also difficult to reconcile with the correlation between
a reduction in PDCs and the severity of arthritis shown
in mice (39) and in humans (40), since PDCs are the
main source of type I IFNs. The most striking demon-
stration of the controversial role of type I IFNs in RA is
perhaps illustrated by 2 publications from the same
group reporting that IFNAR-knockout mice can either
protect (41) or enhance (42) RA pathology, depending
on the model.
In this study, using 3 models of PDC depletion,
we provide substantial evidence for a protective role of
PDCs in inflammatory arthritis (Figure 1 and Supple-
mentary Figures 1–3). We also managed to mobilize
these cells at the inflamed site using topical application
of imiquimod, a TLR-7 ligand. Imiquimod is the active
component of a Food and Drug Administration–
approved topical treatment for superficial basal cell
carcinoma and external genital warts, a process which
is also PDC dependent (28). This simple procedure
exhibited remarkable efficacy for both resolution of
inflammation and protection from bone damage.
Importantly, we demonstrated that this protocol is effi-
cient in 3 different models of arthritis characterized by
different mechanisms of disease initiation and perpetu-
ation (43): the K/BxN serum–transfer model of arthri-
tis, CIA, and human TNF–transgenic mice (Figures 2–4).
Finally, our flow cytometry and transcriptome analyses
(Figure 5) of periarticular tissues revealed that
imiquimod application induces a TLR-7/PDC/type I
IFN cascade that ultimately reduces the proportion of
infiltrating neutrophils, the cytotoxic functions of which
make them major contributors to RA pathology (44).
This is accompanied by an increased number of macro-
phages, whose polarization toward an alternatively acti-
vated phenotype likely contributes to the maintenance
of an antiinflammatory milieu.
Consistent with a previous report describing CpG-
mediated inhibition of serum-transfer arthritis (45), our
data suggest that PDCs are majors players in the regula-
tion of inflammatory reactions in the joint. While the pre-
cise mechanisms of the cellular cross-talk remain to be
deciphered, both imiquimod- and CpG-mediated resolu-
tion of inflammatory arthritis appear to converge toward
a reduction of the neutrophil infiltrate in the joint.
A more thorough transcriptome analysis (using RNA
sequencing) of the inflamed joint following imiquimod
application is needed to identify signatures enabling the
identification and activation status of the different innate
immune cells present in this compartment (46). However,
our work extends these observations beyond the innate
immunity–dependent models of arthritis in mice (namely,
K/BxN serum transfer and human TNF–transgenic mice)
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to the CIA model in which T and B cell activation is
required. Furthermore, the present work points to an
essential role of type I (and possibly type III [47]) IFN
signaling in the protective effect of imiquimod following
experimental arthritis. This is illustrated by the up-
regulation of the ISG CXCL10 which, through its
antiangiogenic properties (48), may also participate in this
therapeutic process. In addition, our data are consistent
with recent observations that enabled a re-evaluation of
the role of IFNb and PDCs in the dampening of excessive
inflammation occurring in various pathologic settings
(49,50).
Up to now, manipulation of DCs for therapeutic
purposes has been accomplished by means of adoptive
transfer, for instance, of PDCs, which confer recovery
from experimental autoimmune encephalomyelitis (49),
or of tolerogenic DCs in RA patients (51). While infu-
sion of autologous tolerogenic DCs appears feasible,
and possibly beneficial (although not yet demonstrated)
in large joints, this expensive procedure is unlikely to
be applicable to the ever-growing number of patients in
developed countries. Furthermore, it does not appear
suitable for smaller joints in which injections remain a
very painful procedure. We believe that mobilization of
PDCs upon topical application of imiquimod, although
not devoid of risks (52), might represent an attractive,
cost-effective, and efficient alternative for improving
the management of RA. A future clinical trial should
clarify this opportunity.
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